Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Rating of "Buy" from Analysts

As of April 1st, 2025, Nkarta, Inc. (NASDAQ:NKTX) has received a consensus rating of "Buy" from a total of eight ratings firms currently covering the company, according to Marketbeat. Out of these, six analysts have assigned a buy rating to the stock, while two have provided a strong buy rating. The average price target set by brokers who have updated their insights over the past year stands at $14.86.

Recent analyst reports on NKTX have highlighted various perspectives. For instance, Stifel Nicolaus adjusted their price target from $15.00 to $14.00, maintaining a "buy" rating for the stock in a report released on March 27th. Similarly, HC Wainwright reiterated its "buy" rating, setting a target price of $18.00 for Nkarta shares. Additionally, Needham & Company LLC reaffirmed a "buy" rating while establishing a price target of $11.00, also on March 27th.

Nkarta's Stock Performance

Nkarta's share price commenced at $1.84 on Thursday. The stock has experienced a one-year low of $1.31 and a one-year high of $11.84. Currently, the company's market capitalization is approximately $130.56 million, with a price-to-earnings (P/E) ratio of -0.98 and a beta of 0.90. The fifty-day moving average price for Nkarta's stock is $1.98, while the 200-day moving average is $2.79.

On March 26th, Nkarta released its latest earnings results, revealing an earnings per share (EPS) of ($0.35) for the quarter. This figure surpassed the consensus estimate of ($0.41) by $0.06. Analysts predict that Nkarta will report an EPS of -1.7 for the ongoing year.

Insider Activity

In related news, CEO Paul J. Hastings sold 17,378 shares of Nkarta on January 15th. The shares were sold at an average price of $2.20, totaling $38,231.60. After the sale, Hastings now holds 319,859 shares in the company, valued at $703,689.80, marking a 5.15% decrease in his ownership. This transaction was reported in a filing with the SEC, accessible through their database. Currently, corporate insiders own about 8.70% of Nkarta's stock.

Institutional Investments in Nkarta

Various institutional investors have recently adjusted their positions in Nkarta. Invesco Ltd. acquired a new stake valued at approximately $30,000 during the fourth quarter. Sequoia Financial Advisors LLC also bought a new position valued at $31,000. Furthermore, Erste Asset Management GmbH invested around $33,000 in the third quarter, while China Universal Asset Management Co. Ltd. and ProShare Advisors LLC acquired positions worth $37,000 and $45,000 respectively in the fourth quarter. Overall, institutional investors and hedge funds now own about 80.54% of Nkarta’s shares.

About Nkarta

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing natural killer cell therapies aimed at treating cancer and autoimmune diseases. The company’s lead product, NKX019, is a chimeric antigen receptor-natural killer (CAR NK) therapy targeting the CD19 antigen. This product is currently in Phase 1 clinical trials for the treatment of relapsed/refractory non-Hodgkin lymphoma, as well as lupus nephritis.

Related Insights

• Five stocks we like better than Nkarta
• The 3 Best Retail Stocks to Shop for in August
• 3 Buyable Stocks With Solid Bottoms Ready to Rebound
• Differences Between Momentum Investing and Long Term Investing
• Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
• Low PE Growth Stocks: Unlocking Investment Opportunities
• Robotaxi News: What Tesla and Lyft Headlines Mean for Shares

Stay Informed - Sign up to receive daily news and ratings summaries for Nkarta and related companies to keep updated on market innovations.

Nkarta, Stock, Analysis